So Dew, your concern is they will have to navigate pricing and marketing a 'superior'- though 'how superior'- drug, all the while confronted with 'inferior' products from generic competition, and penny pinching insurers?
>>main risk for TAF has always been commercial, not medical
Very hard for me to see insurers requiring use of a generic that has an inferior safety profile. I think these results pretty much put your legitimate concern to rest.
Market Data 
Markets 
AI
